Citigroup’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.84M | Buy |
+471,700
| New | +$4.28M | ﹤0.01% | 2165 |
|
|
2025
Q3 | – | Sell |
-42,000
| Closed | -$265K | – | 6241 |
|
|
2025
Q2 | $265K | Hold |
42,000
| – | – | ﹤0.01% | 3932 |
|
|
2025
Q1 | $269K | Sell |
42,000
-158,800
| -79% | -$1.31M | ﹤0.01% | 4017 |
|
|
2024
Q4 | $1.61M | Buy |
200,800
+16,700
| +9% | +$161K | ﹤0.01% | 2975 |
|
|
2024
Q3 | $2.33M | Sell |
184,100
-244,800
| -57% | -$3.16M | ﹤0.01% | 2529 |
|
|
2024
Q2 | $5.43M | Sell |
428,900
-604,800
| -59% | -$6.08M | ﹤0.01% | 1575 |
|
|
2024
Q1 | $4.94M | Sell |
1,033,700
-61,900
| -6% | -$287K | ﹤0.01% | 1711 |
|
|
2023
Q4 | $5.26M | Buy |
1,095,600
+44,000
| +4% | +$269K | ﹤0.01% | 1557 |
|
|
2023
Q3 | $7.61M | Buy |
1,051,600
+744,100
| +242% | +$5.95M | 0.01% | 1234 |
|
|
2023
Q2 | $2.28M | Buy |
307,500
+131,200
| +74% | +$1.03M | ﹤0.01% | 2078 |
|
|
2023
Q1 | $1.22M | Buy |
176,300
+35,300
| +25% | +$325K | ﹤0.01% | 2398 |
|
|
2022
Q4 | $1.45M | Hold |
141,000
| – | – | ﹤0.01% | 2288 |
|
|
2022
Q3 | $2.57M | Sell |
141,000
-125,800
| -47% | -$5.45M | ﹤0.01% | 1968 |
|
|
2022
Q2 | $13.7M | Buy |
266,800
+24,300
| +10% | +$1.26M | 0.01% | 988 |
|
|
2022
Q1 | $17.9M | Sell |
242,500
-158,000
| -39% | -$14.1M | 0.01% | 1003 |
|
|
2021
Q4 | $57.3M | Buy |
400,500
+231,600
| +137% | +$39.8M | 0.03% | 513 |
|
|
2021
Q3 | $35M | Sell |
168,900
-2,700
| -2% | -$595K | 0.02% | 698 |
|
|
2021
Q2 | $36.4M | Buy |
171,600
+21,000
| +14% | +$3.85M | 0.02% | 669 |
|
|
2021
Q1 | $27.3M | Buy |
150,600
+88,300
| +142% | +$17.6M | 0.02% | 784 |
|
|
2020
Q4 | $6.95M | Sell |
62,300
-26,900
| -30% | -$2.86M | ﹤0.01% | 1847 |
|
|
2020
Q3 | $9.66M | Buy |
89,200
+85,200
| +2,130% | +$10.4M | 0.01% | 1404 |
|
|
2020
Q2 | $333K | Sell |
4,000
-800
| -17% | -$30.6K | ﹤0.01% | 4613 |
|
|
2020
Q1 | $65K | Sell |
4,800
-3,380
| -41% | -$28.6K | ﹤0.01% | 5725 |
|
|
2019
Q4 | $33K | Sell |
8,180
-4,900
| -37% | -$21.3K | ﹤0.01% | 6645 |
|
|
2019
Q3 | $66K | Sell |
13,080
-1,915
| -13% | -$10.5K | ﹤0.01% | 5955 |
|
|
2019
Q2 | $88K | Buy |
14,995
+10,040
| +203% | +$79K | ﹤0.01% | 5986 |
|
|
2019
Q1 | $55K | Sell |
4,955
-385
| -7% | -$12.2K | ﹤0.01% | 6265 |
|
|
2018
Q4 | $197K | Buy |
5,340
+3,515
| +193% | +$136K | ﹤0.01% | 5040 |
|
|
2018
Q3 | $69K | Buy |
1,825
+675
| +59% | +$19K | ﹤0.01% | 6247 |
|
|
2018
Q2 | $31K | Buy |
1,150
+100
| +10% | +$3.38K | ﹤0.01% | 6649 |
|
|
2018
Q1 | $44K | Sell |
1,050
-1,435
| -58% | -$57.6K | ﹤0.01% | 6259 |
|
|
2017
Q4 | $62K | Buy |
2,485
+870
| +54% | +$21.2K | ﹤0.01% | 6024 |
|
|
2017
Q3 | $37K | Sell |
1,615
-360
| -18% | -$8.06K | ﹤0.01% | 6150 |
|
|
2017
Q2 | $45K | Sell |
1,975
-2,720
| -58% | -$53.4K | ﹤0.01% | 5861 |
|
|
2017
Q1 | $120K | Sell |
4,695
-640
| -12% | -$17.6K | ﹤0.01% | 5072 |
|
|
2016
Q4 | $134K | Sell |
5,335
-1,880
| -26% | -$54.8K | ﹤0.01% | 5589 |
|
|
2016
Q3 | $300K | Buy |
7,215
+4,115
| +133% | +$531K | ﹤0.01% | 4351 |
|
|
2016
Q2 | $451K | Buy |
3,100
+1,845
| +147% | +$211K | ﹤0.01% | 3775 |
|
|
2016
Q1 | $130K | Sell |
1,255
-320
| -20% | -$34.3K | ﹤0.01% | 5466 |
|
|
2015
Q4 | $264K | Sell |
1,575
-560
| -26% | -$86.2K | ﹤0.01% | 4484 |
|
|
2015
Q3 | $302K | Buy |
2,135
+1,320
| +162% | +$296K | ﹤0.01% | 4184 |
|
|
2015
Q2 | $182K | Buy |
+815
| New | +$143K | ﹤0.01% | 4506 |
|
Other funds holding NVAX
SCM
VPM
VCM
S
Citigroup's NVAX Position: Q1 2026 in Review
Citigroup reduced its Novavax (NVAX) stake by 42% in Q1 2026, selling an estimated $264K and leaving 40,854 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #3757.
Citigroup first reported a position in NVAX in Q2 2013 and has held it in 52 quarters since. The position peaked at $62.9M in Q2 2022. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- Citigroup held 40,854 shares of Novavax worth $333K as of Q1 2026.
- Citigroup sold 29,071 Novavax shares in Q1 2026, an estimated $264K.
- Novavax made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3757 holding.
- Citigroup first reported a position in Novavax in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Novavax position peaked at $62.9M in Q2 2022.
- 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.